BellaSeno is a medical technology company developing bioresorbable scaffold solutions to support tissue regeneration. Its platform uses proprietary polycaprolactone (PCL) scaffolds with interconnected porosity, designed to encourage vascularization and tissue ingrowth as the material gradually resorbs. The approach aims to guide the body’s natural tissue-forming processes without relying on stem cells or biologics.

The company’s current focus is a breast scaffold platform being evaluated for reconstruction, revision procedures, and primary augmentation. BellaSeno reports clinical experience involving 45 patients, with follow-up of up to six years, and has announced positive two-year clinical trial results. It has also entered an exclusive global licensing agreement with Mentor Worldwide LLC, a Johnson & Johnson company, to support further clinical development and preparations for market introduction.

Beyond breast applications, BellaSeno is exploring scaffold-based solutions for chest wall reconstruction and pectus correction, bone reconstruction, and other soft-tissue needs. Its additive manufacturing process is intended to enable reproducible, scalable production. The products are not currently commercially available.